Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Canertinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 9/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Canertinib SCHEMBL29368458 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29655741 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29623482 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL2141065 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL30436576 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL2052123 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL731396 | 0.99 | EGFR (0.97) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL3585133 | 0.93 | EGFR (0.88) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL30415948 | 0.93 | EGFR (0.88) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL13882947 | 0.93 | EGFR (0.86) | EGFRERBB2ERBB4KITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8083 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103823-A1 | COMBINATION OF RAS INHIBITOR AND EGFR INHIBITOR AND USE THEREOF | 广州嘉越医药科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260125490-A1 | Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2026-05-07 | — | — | US | claimed |
| US-12618855-B2 | Serum protein biomarker panel for idiopathic pulmonary fibrosis | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-05-05 | — | — | US | claimed |
| EP-4719387-A2 | COMPLEMENT ANTIBODY-DRUG CONJUGATES | ADS Therapeutics LLC (US) | 2026-04-08 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-12569575-B2 | Radiopaque particle compositions and uses thereof | GUSTAVE ROUSSY TRANSFERT (FR) | 2026-03-10 | — | — | US | claimed |
| US-12559800-B2 | KMT2A-MAML2 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-02-24 | — | — | US | claimed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | claimed |
| WO-2003066060-A2 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-08-14 | — | — | WO | claimed |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-08-07 | — | — | US | claimed |
| EP-1299363-A1 | POLYMORPHIC FORMS/HYDRATES OF N- 4-(3-CHLORO-4-FLUOROPHENYLAMINO)-7-(3-MORPHOLIN-4-YLPROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE DIHYDROCHLORIDE | GÖDECKE GMBH (DE) | 2003-04-09 | — | — | EP | claimed |
| EP-1131304-B1 | N- 4-(3-CHLORO-4-FLUORO-PHENYLAMINO)-7-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE, AN IRREVERSIBLE INHIBITOR OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-12-04 | — | — | EP | claimed |
| US-20020169176-A1 | Method for inhibiting retinoid skin damage | ELDER JAMES T (US) | 2002-11-14 | — | — | US | claimed |
| EP-1230919-A2 | Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| US-6344455-B1 | TREATING CANCER, ATHEROSCLEROSIS, RESTENOSIS, ENDOMETRIOSIS, AND PSORIASIS | WARNER-LAMBERT COMPANY | 2002-02-05 | — | — | US | claimed |
| WO-2002000630-A1 | POLYMORPHIC FORMS/HYDRATES OF N-[4-(3-CHLORO-4-FLUOROPHENYLAMINO)-7-(3-MORPHOLIN-4-YLPROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE DIHYDROCHLORIDE | Gödecke GmbH (DE) | 2002-01-03 | — | — | WO | claimed |
| EP-1131304-A1 | N- 4-(3-CHLORO-4-FLUORO-PHENYLAMINO)-7-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE, AN IRREVERSIBLE INHIBITOR OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 2001-09-12 | — | — | EP | claimed |
| WO-2000031048-A1 | N-[4-(3-CHLORO-4-FLUORO-PHENYLAMINO)-7-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE, AN IRREVERSIBLE INHIBITOR OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 2000-06-02 | — | — | WO | claimed |